Anti-Human IL-17RA (CD217) (Brodalumab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Brodalumab. AMG-827 (Brodalumab) activity is directed against the IL-17 receptor IL-17RA.

Interleukin 17 (IL-17) is a pro-inflammatory cytokine crucial to host defense, tissue repair, pathogenesis of inflammatory disease, and progression of cancer¹. IL-17 signaling is also critical for protection against fungal and bacterial infection². There are six pro-inflammatory cytokines (IL-17A-F) produced by Th17 cells, and the IL-17RA receptor is used by IL-17A, IL-17C, IL- 17E, and IL-17F to promote signaling and downstream responses³. IL-17RA binds IL-17 with coreceptor IL-17RC to initiate signaling events^1,2. Blocking the IL-17RA receptor prevents the release of IL-17-mediated proinflammatory protein kinases and chemokines³. IL-17 and IL- 17RA blockade have therefore been explored as immunotherapy for various autoimmune diseases.

Brodalumab binds with high affinity to human IL-17RA and blocks signaling of IL-17A, F, and A/F heterodimer via the IL-17RA/RC complex as well as IL-17E signaling via the IL-17RA/RB complex 4,5 ^4,5.

Brodalumab is approved to treat moderate to severe plaque psoriasis but was found to make Crohn’s disease worse³. Brodalumab is also known as AMG 827/KHK 4827⁶.

IL-17RA is ubiquitously expressed.

IL-17A, IL-17C, IL-17E, and IL-17F

1. Li X, Bechara R, Zhao J, et al. Nat Immunol. 20(12):1594-1602. 2019.
2. Amatya N, Garg AV, Gaffen SL. Trends Immunol. 38(5):310-322. 2017.
3. Golbari NM, Basehore BM, Zito PM. Brodalumab. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470324/
4. Papp KA, Leonardi C, Menter A, et al. N Engl J Med. 366(13):1181-1189. 2012.
5. Martin DA, Churchill M, Flores-Suarez L, et al. Arthritis Res Ther. 15(5):R164. 2013.
6. Reichert JM. MAbs. 6(1):5-14. 2014.
7. Mease PJ, Genovese MC, Greenwald MW, et al. N Engl J Med. 370(24):2295-2306. 2014.